Skip to main content

Table 2 Stratified analyses of the pooled HRs of overall survival by tumor type, sample size, follow-up months, and survival analysis method

From: Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers

Subgroup analysis

No. of studies

No. of patients

Pooled HR (95% CI)

Heterogeneity

Fixed model

p-value

I2 (%)

p-value

Tumor type

 Digestive system

6

374

2.00 (1.73, 2.31)

0.000

0.0

0.989

 Others

4

316

2.31 (1.84, 2.89)

0.000

0.0

0.573

Sample size

 ≥60

6

505

2.09 (1.84, 2.37)

0.000

0.0

0.932

 < 60

4

185

1.97 (1.16, 3.34)

0.012

0.0

0.681

Follow-up months

 ≥60

7

530

2.09 (1.84, 2.37)

0.000

0.0

0.793

 < 60

3

160

2.02 (1.19, 3.46)

0.01

0.0

0.766

Survival analysis method

 Multivariate

3

223

2.07 (1.78, 2.40)

0.000

30.6

0.237

 Univariate

7

467

2.12 (1.71, 2.63)

0.000

0.0

0.993

  1. CI confidence interval, HR hazard ratio